Aztreonam and avibactam combination therapy for metallo-β …
2024年11月9日 · Aztreonam/avibactam (ATM/AVI) recently emerged as a promising option, which restores the monobactam effectiveness against specific β-lactamases, enhancing their antimicrobial activity with a non-β-lactam β-lactamase inhibitor.
Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer …
2023年6月1日 · The combination of aztreonam with avibactam restores aztreonam’s activity against bacteria that co-produce MBLs and other β-lactamases and, if approved, could offer a much-needed safe and effective treatment option against multidrug-resistant Gram …
European Commission Approves Pfizer’s EMBLAVEO® for …
2024年4月22日 · (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for EMBLAVEO ® (aztreonam-avibactam) for the treatment of adult patients with complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), and complicated urinary tract ...
Emblaveo | European Medicines Agency (EMA)
2024年3月22日 · Emblaveo is an antibiotic used in adults to treat: Infections due to certain types of bacteria called aerobic gram-negative bacteria when patients have limited treatment options. Emblaveo contains the active substances aztreonam and avibactam. How is Emblaveo used? How does Emblaveo work? What benefits of Emblaveo have been shown in studies?
Aztreonam-avibactam and cefepime-enmetazobactam now …
2024年3月5日 · Aztreonam-avibactam has now obtained regulatory approval and breakpoints from EMA and EUCAST for Enterobacterales. These are S≤4, R>4 mg/L.Disk diffusion criteria and QC targets and ranges will be published shortly. There are no breakpoints for other species.
New antibiotic to fight infections caused by multidrug-resistant ...
2024年3月22日 · Microbiology data indicate that aztreonam in combination with avibactam will be effective in infections caused by many multidrug-resistant aerobic Gram-negative pathogens and the combination could therefore address an unmet medical need.
The Revival of Aztreonam in Combination with Avibactam …
We performed a systematic review including 35 in vitro and 18 in vivo studies on the combination aztreonam + avibactam for infections sustained by MBL-producing Gram-negatives.
Aztreonam–avibactam versus meropenem for the treatment of …
2024年10月7日 · Aztreonam–avibactam (with or without metronidazole) was efficacious in treating patients with complicated intra-abdominal infection and HAP–VAP (including severely ill patients and those with previous treatment failure); clinical cure and microbiological response rates were similar to the comparator treatment, meropenem (with or without ...
Aztreonam–avibactam: The dynamic duo against …
2024年11月27日 · Aztreonam–avibactam (ATM–AVI) is a promising new combination therapy designed to combat multidrug-resistant (MDR) gram-negative bacteria, including those producing metallo-β-lactamases (MBLs). Aztreonam, a monobactam antibiotic, is resistant to hydrolysis by MBLs but can be degraded by other β-lactamases. Avibactam, a novel non-β-lactam ...
Aztreonam– avibactam (ATM–AVI) is a promising new combination therapy designed to combat multidrug- resistant (MDR) gram- negative bacteria, including those producing metallo- β- lactamases (MBLs). Aztreonam, a monobactam antibiotic, is resistant to hydrolysis by MBLs but can be degraded by other β- lactamases.
- 某些结果已被删除